The performance of companies tied to the drug's past presents a intricate investment scenario . While the initial boom generated substantial profits , generic alternatives have significantly eroded sales . Investing in associated pharmaceutical companies now requires a careful assessment of proprietary protection , evolving healthcare changes, and